Drug Profile

RBN 012759

Alternative Names: RBN-012759

Latest Information Update: 20 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ribon Therapeutics
Class Antineoplastics; Cyclohexanols; Cyclopropanes; Fluorinated hydrocarbons; Organic sulfur compounds; Quinazolinones; Small molecules
Mechanism of Action PARP14 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Cancer; Inflammation

Most Recent Events

20 Oct 2023 Discontinued - Preclinical for Cancer in USA (PO) prior to October 2023 (Ribon Therapeutics pipeline, October 2023)
20 Oct 2023 Discontinued - Preclinical for Inflammation in USA (PO) prior to October 2023 (Ribon Therapeutics pipeline, October 2023)
10 Apr 2021 Preclinical trials in Inflammation in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com